Cargando…

MHC class II restricted neoantigen peptides predicted by clonal mutation analysis in lung adenocarcinoma patients: implications on prognostic immunological biomarker and vaccine design

BACKGROUND: Mutant peptides presented by MHC (major histocompatibility complex) Class II in cancer are important targets for cancer immunotherapy. Both animal studies and clinical trials in cancer patients showed that CD4 T cells specific to tumor-derived mutant peptides are essential for the effica...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cai, Weijing, Zhou, Dapeng, Wu, Weibo, Tan, Wen Ling, Wang, Jiaqian, Zhou, Caicun, Lou, Yanyan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6090856/ https://www.ncbi.nlm.nih.gov/pubmed/30075702 http://dx.doi.org/10.1186/s12864-018-4958-5

Ejemplares similares

Immunogenicity of Del19 EGFR mutations in Chinese patients affected by lung adenocarcinoma
por: Pan, Deng, et al.
Publicado: (2019)

Creating MHC-Restricted Neoantigens with Covalent Inhibitors That Can Be Targeted by Immune Therapy
por: Hattori, Takamitsu, et al.
Publicado: (2023)

Neoantigen characteristics in the context of the complete predicted MHC class I self-immunopeptidome
por: Brown, Scott D., et al.
Publicado: (2018)

Identical peptides recognized by MHC class I- and II-restricted T cells
Publicado: (1989)

Immunological analysis of hybrid neoantigen peptide encompassing class I/II neoepitope-pulsed dendritic cell vaccine
por: Morisaki, Shinji, et al.
Publicado: (2023)

A conjoined universal helper epitope can unveil antitumor effects of a neoantigen vaccine targeting an MHC class I-restricted neoepitope
por: Swartz, Adam M., et al.
Publicado: (2021)

The impact of DM on MHC class II–restricted antigen presentation can be altered by manipulation of MHC–peptide kinetic stability
por: Lazarski, Christopher A., et al.
Publicado: (2006)

Precision Neoantigen Discovery Using Large-scale Immunopeptidomes and Composite Modeling of MHC Peptide Presentation
por: Pyke, Rachel Marty, et al.
Publicado: (2021)

Thymus dictates major histocompatibility complex (MHC) specificity and immune response gene phenotype of class II MHC-restricted T cells but not of class I MHC-restricted T cells
Publicado: (1984)

HLA class-I and class-II restricted neoantigen loads predict overall survival in breast cancer
por: Ren, Yingxue, et al.
Publicado: (2020)

MHC-II neoantigens shape tumor immunity and response to immunotherapy
por: Alspach, Elise, et al.
Publicado: (2019)

Apparent lack of MHC restriction in binding of class I HLA molecules to solid-phase peptides
Publicado: (1990)

Identification of KRAS G12V associated clonal neoantigens and immune microenvironment in long-term survival of pancreatic adenocarcinoma
por: Wang, Chao, et al.
Publicado: (2021)

Identification of Novel HLA Class II-Restricted Neoantigens Derived from Driver Mutations
por: Iiizumi, Susumu, et al.
Publicado: (2019)

Identification of HLA class I-restricted immunogenic neoantigens in triple negative breast cancer
por: Aparicio, Belén, et al.
Publicado: (2022)

Generation of novel complete HLA class I monoallelic cell lines used in an MHC stabilization assay for neoantigen evaluation
por: Iizuka, Akira, et al.
Publicado: (2023)

Restricted MHC–peptide repertoire predisposes to autoimmunity
por: Logunova, Nadezda N., et al.
Publicado: (2005)

Immunological Functions of the Membrane Proximal Region of MHC Class II Molecules
por: Harton, Jonathan, et al.
Publicado: (2016)

Tumor neoantigens: from basic research to clinical applications
por: Jiang, Tao, et al.
Publicado: (2019)

Hepatobiliary Tumor Organoids Reveal HLA Class I Neoantigen Landscape and Antitumoral Activity of Neoantigen Peptide Enhanced with Immune Checkpoint Inhibitors
por: Wang, Wenwen, et al.
Publicado: (2022)

Predicting T cell recognition of MHC class I restricted neoepitopes
por: Koşaloğlu-Yalçın, Zeynep, et al.
Publicado: (2018)

Peptide and Peptide-Dependent Motions in MHC Proteins: Immunological Implications and Biophysical Underpinnings
por: Ayres, Cory M., et al.
Publicado: (2017)

Monitoring the Dynamics of T Cell Clonal Diversity Using Recombinant Peptide:MHC Technology
por: Blanchfield, J. Lori, et al.
Publicado: (2013)

Association of CD99 short and long forms with MHC class I, MHC class II and tetraspanin CD81 and recruitment into immunological synapses
por: Pata, Supansa, et al.
Publicado: (2011)

The MHC class I peptide repertoire is molded by the transcriptome
por: Fortier, Marie-Hélène, et al.
Publicado: (2008)

Motifs and supermotifs for MHC class II binding peptides
Publicado: (1995)

Linkage of Bacterial Protein Synthesis and Presentation of MHC Class I-Restricted Listeria monocytogenes-Derived Antigenic Peptides
por: Grauling-Halama, Silke, et al.
Publicado: (2012)

Influence of DM-sensitivity on immunogenicity of MHC class II restricted antigens
por: Bernhardt, Anna Luise, et al.
Publicado: (2021)

Enhanced presentation of MHC class Ia, Ib and class II-restricted peptides encapsulated in biodegradable nanoparticles: a promising strategy for tumor immunotherapy
por: Ma, Wenxue, et al.
Publicado: (2011)

An effective peptide vaccine strategy circumventing clonal MHC heterogeneity of murine myeloid leukaemia
por: Shin, A-Ri, et al.
Publicado: (2020)

Facile repurposing of peptide–MHC-restricted antibodies for cancer immunotherapy
por: Yang, Xinbo, et al.
Publicado: (2023)

The V beta complementarity determining region 1 of a major histocompatibility complex (MHC) class I-restricted T cell receptor is involved in the recognition of peptide/MHC I and superantigen/MHC II complex
Publicado: (1994)

Model for the Peptide-Free Conformation of Class II MHC Proteins
por: Painter, Corrie A., et al.
Publicado: (2008)

Non-conventional sources of peptides presented by MHC class I
por: Starck, Shelley R., et al.
Publicado: (2011)

Prediction of MHC class I binding peptides, using SVMHC
por: Dönnes, Pierre, et al.
Publicado: (2002)

Regulation of MHC Class II-Peptide Complex Expression by Ubiquitination
por: Cho, Kyung-Jin, et al.
Publicado: (2013)

Properties of MHC Class I Presented Peptides That Enhance Immunogenicity
por: Calis, Jorg J. A., et al.
Publicado: (2013)

A Peptide Filtering Relation Quantifies MHC Class I Peptide Optimization
por: Dalchau, Neil, et al.
Publicado: (2011)

Citrullination only infrequently impacts peptide binding to HLA class II MHC
por: Sidney, John, et al.
Publicado: (2017)

Heterogeneity of neoantigen landscape between primary lesions and their matched metastases in lung cancer
por: Jiang, Tao, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_b37jti0v3eis85qbva2e9oaqbp